Odiya (abatacept) nke US Food and Drug Administration (FDA) nyere aka na Dec 23, 2005 dịka ọgwụ ọhụrụ iji mee ihe ịrịba ama na ihe mgbaàmà nke ọrịa ogbu na nkwonkwo . Orencia sonyeere ndị DMARD atọ ọzọ n'oge na-akwụsịlata mmebi nke mmebi iwu, gụnyere ihe ndị na-akpata necrosis na-akpata (anti-TNF):
Simponi (golimumab) na Cimzia (certolizumab pegol), abụọ ndị na-egbochi TNF, ka akwadochara.
A kwadoro Orencia maka ndị na-arịa ọrịa ogbu na nkwonkwo nke na-arụsi ọrụ ike bụ ndị na-enweghi mmeghachi omume na otu n'ime ọgwụ ndị na-agbanwe ọrịa ahụ (DMARDs) nke na-agbakwunye ndị na-ebute TNF gụnyere:
- Rheumatrex (methotrexate)
- Arava (leflunomide)
- Plaquenil (hydroxychloroquine)
- Azulfidine (sulfasalazine)
Edoro Orencia
Dị ka ihe nkedo (nke nta), Orencia nyere dị ka ngwakọta na-egbuke egbuke (IV). A na-elekọta Orencia ihe karịrị nkeji 30, n'adịghị ka infliximab nke a na-elekọta ihe dịka awa abụọ.
Mgbe nchịkwa mbụ ahụ gasịrị, a na-enye Orencia na izu 2 na izu anọ, mgbe izu anọ ọ bụla gasịrị. Orencia nwere ike iji dịka ụbụrụ (nanị) ma ọ bụ na-ejikọta ya na ndị ọzọ DMARD ndị na-abụghị ndị na-ebute TNF n'ihi ịdaba na-arịwanye elu nke nro na nchikota.
N'ihe dị ka na July 2011, FDA kwadoro ịmepụta onwe onye n'ime onwe ya nke Orencia.
Njirimara Na-emetụta Njikọ Orencia
Mmetụta ndị metụtara gụnyere mana esighị na:
- mmeghachi omume na-adịghị ahụ ụfụ nke na-adịkarịghị adị ndụ egwu
- ọrịa
- nsogbu iku ume iku ume (karịsịa na ndị ọrịa na-arịa ọrịa mkpọnwụ na-adịghị ala ala)
Eziokwu iche echiche tupu ị gbalịa Orencia
Ọnụahịa nke Orencia tinyere nlekota ya yiri ka ọ bụ karịa TNF na-agbanye adalimumab na inanceptcept but less than infliximab. Orencia egosipụtara nanị uru dị nro mgbe eji ya naanị ya ka ọ dị mma iji DMARD ọzọ dịka ụkpụrụ ma ọ bụ ndị ọzọ iji nweta nsonaazụ dị mma.
Ruo mgbe enwere ahụmahụ ọzọ gbasara ahụike na Orencia, ụfọdụ ndị dọkịta na-edebe ya maka ndị ọrịa na-akụda ma ọ dịkarịa ala abụọ n'ime ndị na-emegide TNF atọ (atụpụtara site na mmetụta ndị na-adịghị mma ma ọ bụ enweghị uru). Ugbo ogwu arthritis abiawo n'uwa ebe obu na etiti nabatara na 1999 ma gosiputa onodu bara uru bara uru.
Orencia vs. Anakinra
Anakinra na-ejikarị eme ihe banyere ọrịa ogbu na nkwonkwo n'ihi mkpa ọ dị maka injections kwa ụbọchị na uru dị ntakịrị ma e jiri ya tụnyere ndị na-emegide TNF nke na-egbochi ọrụ nke TNF (cytokine ma ọ bụ ozi n'etiti mkpụrụ ndụ). TNF bụ onyinye nke nwere oke ọrụ na-akpata nsị na mmebi n'ime ọrịa ogbu na nkwonkwo.
Mkpụrụ ndụ T na-etinyekwa aka na-eme ka ihe ịrịba ama na mgbaàmà nke ọrịa arthritis rheumatoid. Orencia na-agbanye mgbaàmà n'ime ọbara dị mkpa maka mkpụrụ ndụ T iji mee mmebi ha.
Kineret (anakinra) na-egbochi cytokine IL-1 nke na-arụ ọrụ n'ime mmebi ọkpụkpụ nke bụ akụkụ nke ọrịa ogbu na nkwonkwo.
Azịza nke Scott J. Zashin, MD, bụ ọkachamara na-enyere ndị ọkachamara aka na University nke Texas Southwestern Medical School, Division of Rheumatology, na Dallas, Texas. Dr. Zashin bụkwa onye dọkịta nọ na Presbyterian Hospital nke Dallas na Plano. Ọ bụ onye ibe nke American College of Physicians and the American College of Rheumatology na onye òtù nke American Medical Association.